Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models.
about
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activityTau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseTherapeutic and diagnostic challenges for frontotemporal dementiaMethylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerioMethylene blue reduced abnormal tau accumulation in P301L tau transgenic miceAcute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivoAn aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.The rise and fall of Dimebon.Influence of methylene blue on microglia-induced inflammation and motor neuron degeneration in the SOD1(G93A) model for ALS.Targeting RNA binding proteins involved in neurodegeneration.Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice.Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer DiseaseNeuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease.Dimebolin in dementia.Treatment implications of C9ORF72.Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseasesTargeting TDP-43 in neurodegenerative diseases.Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine).Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity.The role of endoplasmic reticulum stress in neurodegenerative disease.Differential diagnosis of amyotrophic lateral sclerosis from Guillain-Barré syndrome by quantitative determination of TDP-43 in cerebrospinal fluid.Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS.An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models.Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region.Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast.A Small Molecule Impedes Insulin Fibrillation: Another New Role of Phenothiazine Derivatives.Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?Molecular dissection of TDP-43 proteinopathies.Pharmacological Agents Targeting the Cellular Prion Protein.[Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].
P2860
Q24634209-A022A850-34B1-4B96-9C47-1176D176F914Q26739412-E96099E9-2194-4AB1-8857-06373D642DF0Q26998919-AE017F50-0A17-43BB-BE75-BE9994320C01Q27329440-EFAA06E2-51F6-48C2-9169-D8F1DA9432CEQ28484481-CA83E245-2B71-4B5B-8F6F-1483FAB590A2Q33592247-183A5089-6BB6-4EAE-B6AB-26878E2B8B83Q34066654-A7607393-AD0F-449C-AB57-938FBE196D4AQ34146766-035BEBFA-3D7C-4D28-A9CF-F0E50EE6B35DQ34405946-58A012CC-DB45-4490-B7BB-0B60BD526075Q34954162-DBE4F2F1-18CF-4D93-9C06-262BE43EB6F4Q35940409-70D9FE98-08B0-41D2-8E74-2AFA21FF0F5DQ35957568-9A328667-CB2B-4E1C-8227-FFA5FE32B4DFQ36273566-FA75A348-E2B4-4F5F-BD7D-8A88A32DB1D1Q37736181-245CEE02-2588-4B06-B542-F9D782029F5DQ37765630-A4D59155-7B4A-40C8-B317-DAD7D5A8A72CQ38062966-1DDC2DA7-1CC3-4639-A675-9AE78EB84631Q38168475-96234A79-6544-41B0-B9B9-DB5248F93689Q38197689-241587F7-29BB-4B41-BAF6-D55C2D3D5CC2Q38540347-43D2E2D6-FD93-4B9D-B28C-5516B119A3CAQ38603960-CE95EB2F-ADBE-408E-8F89-695DE73058CFQ38624671-8EB89AD5-AC9C-4873-9C6D-231FAFF3A5C1Q38625515-47E89B6C-B163-4B6E-9101-636FA9E0D22DQ38715233-56A4A8E0-E5DA-4831-B4DC-71B12A00B74BQ38797404-E7749DBC-6EF1-496E-8712-D16805F2ED2AQ38999268-1FD9510B-E746-4AED-8AF8-743321B078F3Q39091938-6340738E-EFF0-45C4-BB76-4B970CD7DD8FQ39517613-150D1392-02EF-44A0-942F-105F96630F5CQ39612001-C89765B4-1C88-401E-8C8E-815756556183Q41819989-558DB78F-22AB-4CD5-8454-B9A6FAA64589Q42115187-CD750EF5-34F0-4D6A-AC25-9FDBD08A313DQ47215265-5170C197-1B23-42E4-8DD7-6B7CA81F1072Q48239696-D6D758F4-9907-42BF-A572-67083CB5154CQ49160878-1359EDC2-E1CB-4BEA-A708-014E4FBD920CQ52666286-E061908C-AAE1-463D-B115-576B2E57DE3CQ53312752-83A28D3D-7608-4C57-9150-FBDC345F7D5B
P2860
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models.
@en
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models.
@nl
type
label
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models.
@en
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models.
@nl
prefLabel
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models.
@en
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models.
@nl
P2093
P2860
P1433
P1476
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models
@en
P2093
Fuyuki Kametani
Haruhiko Akiyama
Makiko Yamashita
Masato Hasegawa
Michel Goedert
Natalia Ninkina
Sergey O Bachurin
Tetsuaki Arai
P2860
P304
P356
10.1016/J.FEBSLET.2009.06.042
P407
P577
2009-06-26T00:00:00Z